Application of boosted trees to the prognosis prediction of COVID-19.

COVID‐19 XGBoost explainable boosting machine machine learning prediction prognosis

Journal

Health science reports
ISSN: 2398-8835
Titre abrégé: Health Sci Rep
Pays: United States
ID NLM: 101728855

Informations de publication

Date de publication:
May 2024
Historique:
received: 03 06 2023
revised: 07 02 2024
accepted: 18 04 2024
medline: 24 5 2024
pubmed: 24 5 2024
entrez: 24 5 2024
Statut: epublish

Résumé

The precise prediction of COVID-19 prognosis remains a clinical challenge. In this regard, early identification of severe cases facilitates the triage and management of COVID-19 cases. The present paper aims to explore the prognosis of COVID-19 patients based on routine laboratory tests taken when patients are admitted. A data set including 1455 COVID-19 patients (727 male, 728 female) and their routine laboratory tests conducted upon hospital admission, age, Intensive Care Unit (ICU) admission, and outcome were gathered. The data set was randomly split into the train (75% of the data) and test data set (25% of the data). The explainable boosting machine (EBM) and extreme gradient boosting (XGBoost) were used for predicting the mortality and ICU admission of COVID-19 cases. Also, feature importance was extracted using EBM and XGBoost. The EBM and XGBoost achieved 86.38% and 88.56% accuracy in the test data set, respectively. In addition, EBM and XGBoost predicted the ICU admission with an accuracy of 89.37%, and 79.29% in the test data set for COVID-19 patients, respectively. Also, obtained models indicated that aspartate transaminase (AST), lymphocyte, blood urea nitrogen (BUN), and age are the most significant predictors of COVID-19 mortality. Furthermore, the lymphocyte count, AST, and BUN level were the most significant ICU admission predictors of COVID-19 patients. The current study indicated that both EBM and XGBoost could predict the ICU admission and mortality of COVID-19 cases based on routine hematological and clinical chemistry evaluation at the time of admission. Also, based on the results, AST, lymphocyte count, and BUN levels could be used as early predictors of COVID-19 prognosis.

Sections du résumé

Background and Aims UNASSIGNED
The precise prediction of COVID-19 prognosis remains a clinical challenge. In this regard, early identification of severe cases facilitates the triage and management of COVID-19 cases. The present paper aims to explore the prognosis of COVID-19 patients based on routine laboratory tests taken when patients are admitted.
Methods UNASSIGNED
A data set including 1455 COVID-19 patients (727 male, 728 female) and their routine laboratory tests conducted upon hospital admission, age, Intensive Care Unit (ICU) admission, and outcome were gathered. The data set was randomly split into the train (75% of the data) and test data set (25% of the data). The explainable boosting machine (EBM) and extreme gradient boosting (XGBoost) were used for predicting the mortality and ICU admission of COVID-19 cases. Also, feature importance was extracted using EBM and XGBoost.
Results UNASSIGNED
The EBM and XGBoost achieved 86.38% and 88.56% accuracy in the test data set, respectively. In addition, EBM and XGBoost predicted the ICU admission with an accuracy of 89.37%, and 79.29% in the test data set for COVID-19 patients, respectively. Also, obtained models indicated that aspartate transaminase (AST), lymphocyte, blood urea nitrogen (BUN), and age are the most significant predictors of COVID-19 mortality. Furthermore, the lymphocyte count, AST, and BUN level were the most significant ICU admission predictors of COVID-19 patients.
Conclusions UNASSIGNED
The current study indicated that both EBM and XGBoost could predict the ICU admission and mortality of COVID-19 cases based on routine hematological and clinical chemistry evaluation at the time of admission. Also, based on the results, AST, lymphocyte count, and BUN levels could be used as early predictors of COVID-19 prognosis.

Identifiants

pubmed: 38784249
doi: 10.1002/hsr2.2104
pii: HSR22104
pmc: PMC11111612
doi:

Types de publication

Journal Article

Langues

eng

Pagination

e2104

Informations de copyright

© 2024 The Author(s). Health Science Reports published by Wiley Periodicals LLC.

Déclaration de conflit d'intérêts

The authors declare no conflict of interest.

Auteurs

Sajjad Molaei (S)

Department of Computer Engineering Amirkabir University of Technology Tehran Iran.

Hadi Moazen (H)

Department of Computer Science and Software Engineering Universite Laval Quebec Quebec Canada.

Hamid R Niazkar (HR)

Breast Diseases Research Center Shiraz University of Medical Sciences Shiraz Iran.

Masoud Sabaei (M)

Department of Computer Engineering Amirkabir University of Technology Tehran Iran.

Masoumeh G Johari (MG)

Breast Diseases Research Center Shiraz University of Medical Sciences Shiraz Iran.

Abbas Rezaianzadeh (A)

Colorectal Research Center Shiraz University of Medical Sciences Shiraz Iran.

Classifications MeSH